<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="236125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005803</url>
  </required_header>
  <id_info>
    <org_study_id>1409.00</org_study_id>
    <secondary_id>NCI-2010-00130</secondary_id>
    <secondary_id>1409.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00005803</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma</brief_title>
  <official_title>A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies how well autologous stem cell transplant followed by donor
      stem cell transplant works in treating patients with lymphoma that has returned or does not
      respond to treatment. Peripheral blood stem cell transplant using stem cells from the
      patient or a donor may be able to replace immune cells that were destroyed by chemotherapy
      used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer
      cells (graft-versus-tumor effect).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate engraftment of human leukocyte antibody (HLA) identical peripheral blood stem
      cell (PBSC) allografts given after conditioning with total-body irradiation (TBI) (200cGy)
      +/- fludarabine (fludarabine phosphate), 90 mg/m^2 and post-grafting immunosuppression with
      cyclosporine (CSP)/mycophenolate mofetil (MMF) in refractory or relapsed lymphoma patients
      following an initial autologous peripheral blood stem cell transplant (PBSCT) for disease
      cytoreduction.

      II. To determine the non-relapse mortality at day 100 post-non-myeloablative allografting
      following mobilization and high-dose chemotherapy with autografting.

      SECONDARY OBJECTIVES:

      I. To determine the disease free survival and overall survival of non-myeloablative
      allografting following autologous PBSCT.

      OUTLINE:

      CONDITIONING REGIMEN: Patients with matched, related stem cell donors receive
      cyclophosphamide intravenously (IV) on days -6 and -5 and undergo TBI twice daily (BID) on
      days -3 to -1. Patients with matched, unrelated stem cell donors receive carmustine IV over
      3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, and cytarabine IV over 3
      hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.

      TRANSPLANTATION: All patients undergo autologous PBSCT on day 0.

      NON-MYELOABLATIVE CONDITIONING: Beginning 40-120 days following PBSC transplant, patients
      with related donors undergo TBI on day 0. Patients with unrelated donors receive fludarabine
      phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.

      TRANSPLANTATION: Patients undergo non-myeloablative allogeneic PBSCT on day 0.

      IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) BID on days -3 to 56 (patients
      with related donors) or 100 (patients with unrelated donors) followed by taper to day 180.
      Patients also receive mycophenolate mofetil PO BID on days 0-27 (patients with related
      donors) or thrice daily (TID) on days 0-27, then BID on days 28-40 followed by taper to day
      96 (patients with unrelated donors).

      Some patients may undergo donor lymphocyte infusion if there is evidence of disease
      progression and no evidence of graft-vs-host disease (GVHD).

      After completion of study treatment, patients are followed up at day 180, 1 year, 1.5 years,
      2 years, 3 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 1999</start_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment of HLA identical PBSC allografts</measure>
    <time_frame>Day 56</time_frame>
    <description>The rates and accompanying confidence intervals associated with failure of engraftment at day +56 will be calculated after every 5th patient is enrolled on the study. If the lower limit to the appropriate one-sided 80% confidence interval exceeds 25%, this will be considered sufficient evidence of an excess &quot;failure&quot; rate and the study will be stopped. For these purposes, all patients will be evaluated together (patients with chemosensitive and chemoresistant disease).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Day 100 post-non-myeloablative allografting following mobilization and high-dose chemotherapy with autografting</time_frame>
    <description>The rates and accompanying confidence intervals associated with transplant-related mortality will be calculated after every 5th patient is enrolled on the study. If the lower limit to the appropriate one-sided 80% confidence interval exceeds 25%, this will be considered sufficient evidence of an excess &quot;failure&quot; rate and the study will be stopped. For these purposes, all patients will be evaluated together (patients with chemosensitive and chemoresistant disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of autologous transplant until the time of death, assessed up to 17 years</time_frame>
    <description>Though OS will be analyzed for the trial as a whole, chemosensitive and chemoresistant patients will be analyzed separately for OS for comparison to their respective historical controls. These groups will be looked at separately to gather preliminary data on whether or not there appears to be a difference in the OS among patients who had chemosensitive vs chemoresistant disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free-survival (PFS)</measure>
    <time_frame>From the date of autologous transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, assessed at 3 years</time_frame>
    <description>Though PFS will be analyzed for the trial as a whole, chemosensitive and chemoresistant patients will be analyzed separately for PFS for comparison to their respective historical controls. These groups will be looked at separately to gather preliminary data on whether or not there appears to be a difference in the PFS among patients who had chemosensitive vs chemoresistant disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Childhood Hodgkin Lymphoma</condition>
  <condition>Recurrent Childhood Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Chronic Lymphocytic Leukemia</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Small Lymphocytic Lymphoma</condition>
  <condition>T-Cell Chronic Lymphocytic Leukemia</condition>
  <condition>T-Cell Prolymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous transplantation</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>auto-allo HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Oforta</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic transplantation</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic transplantation</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Therapeutic Autologous Lymphocytes</intervention_name>
    <description>IV donor lymphocyte infusion</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>Autologous T-cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (tandem transplantation)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lymphoma (non-Hodgkin lymphoma [NHL], chronic lymphocytic
             leukemia/small lymphocytic lymphoma [CLL/SLL] or Hodgkin's lymphoma) with primary
             refractory or relapsed disease after standard chemotherapy at high risk of relapse
             with conventional autografting; patients with a diagnosis of CLL (or small
             lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia
             (PLL), or T-cell CLL or PLL

          -  Must have an HLA genotypically or phenotypically identical related donor or, at a
             minimum, a high likelihood of identifying an HLA-matched unrelated donor; the
             determination of availability of a suitable unrelated donor may be based on a
             World-Book search

          -  Cross-over to other tandem autologous-allogeneic research protocol (#2241) will be
             allowed if the patient loses the suitable HLA-matched related or unrelated donor but
             has an available HLA-haploidentical donor before receiving the allogeneic
             transplantation and if the patient meets the eligibility criteria of the subsequent
             study

          -  Cross-over from other tandem autologous-allogeneic research protocol (#2241) will be
             allowed if a suitable HLA-matched related or unrelated donor is identified before
             receiving the allogeneic transplantation and if the patient meets the eligibility
             criteria of the subsequent study

          -  Signed informed consent

          -  Detectable tumor on radiographic studies or bone marrow biopsy prior to mobilization
             regimen

          -  Expected survival &gt;= 3 months from study entry

          -  DONOR: HLA genotypically or phenotypically identical related donor

          -  DONOR: Must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim)
             administration and leukapheresis for both PBSC allograft and subsequent donor
             lymphocyte infusion (DLI)

          -  DONOR: Must have adequate veins for leukapheresis or agree to placement of central
             venous catheter (femoral or subclavian)

          -  DONOR: Age &lt; 75 years (yrs), older donors may be considered after review at Patient
             Care Conference

          -  DONOR: Fred Hutchinson Cancer Research Center (FHCRC) matching allowed will be grades
             1.0 to 2.1; unrelated donors who are prospectively: matched for HLA-A, B, C, DRB1 and
             DQB1 by high resolution typing; only a single allele disparity will be allowed for
             HLA-A, B, or C as defined by high resolution typing

          -  DONOR: Donors are excluded when preexisting immunoreactivity is identified that would
             jeopardize donor hematopoietic cell engraftment; this determination is based on the
             standard practice of the individual institution; the recommended procedure for
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
             reactive antibody (PRA) screens to class I and class II antigens for all patients
             before HCT; if the PRA shows &gt; 10% activity, then flow cytometric or B and T cell
             cytotoxic cross matches should be obtained; the donor should be excluded if any of
             the cytotoxic cross match assays are positive; for those patients with an HLA class I
             allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be
             obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is
             an absolute donor exclusion

          -  DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft
             rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101
             and the donor is A*0102, and this type of mismatch is not allowed

          -  DONOR: Only G-CSF mobilized peripheral blood mononuclear cells (PBMC) only will be
             permitted as a hematopoietic stem cell (HSC) source on this protocol

        Exclusion Criteria:

          -  Life expectancy severely limited by disease other than lymphoma

          -  Prior autologous hematopoietic stem cell transplant

          -  Patients at high risk of veno-occlusive disease of the liver (criteria not yet
             rigorously defined but includes bilirubin &gt; 2.0 mg and serum glutamic oxaloacetic
             transaminase [SGOT] or serum glutamate pyruvate transaminase [SGPT] &gt; 2 x normal);
             patients may be accepted outside of this range if cleared by gastrointestinal (GI)
             consult

          -  Cardiac ejection fraction (EF) &lt; 40% on multi-gated acquisition (MUGA) scan or
             cardiac echocardiogram (echo) (or if unable to obtain ejection fraction, shortening
             fraction of &lt; 26%); patients with active or a history of cardiac disease should be
             evaluated with appropriate cardiac studies and/or consult; ejection fraction is
             required if age &gt; 50 years or there is a history of anthracyclines or history of
             cardiac disease; patients with a shortening fraction &lt; 26% may be enrolled if
             approved by a cardiologist

          -  Baseline serum-creatinine &gt; 2.0 mg/dl and a calculated or measured creatinine
             clearance of &lt; 50 ml/minute

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Pulmonary dysfunction as measured by a corrected diffusing capacity of the lung for
             carbon monoxide (DLCO) &lt; 50% of predicted total lung capacity (TLC) &lt; 30%, forced
             expiratory volume in 1 second (FEV1) &lt; 30% and/or receiving supplementary continuous
             oxygen; the FHCRC principal investigator (PI) of the study must approve enrollment of
             all patients with pulmonary nodules

          -  Pregnancy or breast-feeding

          -  Patients with poorly controlled hypertension despite hypertensive medication

          -  Karnofsky score less than 60; pediatric criteria: Lansky Play-Performance Score &lt; 40

          -  Patients with cluster of differentiation (CD)34 selected auto grafts

          -  Patients with active non-hematologic malignancies (except non-melanoma skin cancers);
             this exclusion does not apply to patients with non-hematologic malignancies that do
             not require therapy

          -  Patients with a history of non-hematologic malignancies (except non-melanoma skin
             cancers) currently in a complete remission, who are less than 5 years from the time
             of complete remission, and have a &gt; 20% risk of disease recurrence; this exclusion
             does not apply to patients with non-hematologic malignancies that do not require
             therapy

          -  DONOR: Identical twin

          -  DONOR: Age less than 12 years

          -  DONOR: Pregnancy

          -  DONOR: Human immunodeficiency virus (HIV) seropositivity

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness

          -  DONOR: Failure to meet FHCRC criteria for stem cell donation

          -  DONOR: Donor (or centers) who will exclusively donate marrow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maloney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 23, 2016</lastchanged_date>
  <firstreceived_date>June 2, 2000</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
